ALLO - Earnings call transcript Q3 2019 | Allogene Therapeutics, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good morning, ladies and gentlemen, and thank you for standing by. And welcome to Allogene Therapeutics Third Quarter 2019 Conference Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised today’s conference will be recorded.

turn over to Chief Christine like Officer. Communications would the to conference Cassiano, I Ms. go ahead. may you Cassiano,

Christine Cassiano

Thank and you, operator, good morning.

on Therapeutics exclusive Before two market provides press the with a an results and the XXXX. The quarter press issued www.allogene.com. iPSC-based available Notch collaboration for releases. One corporate releases therapies, opened press our release other today, and at to develop Allogene ending website, financial XX, AlloCAR update discusses are September

webcast listeners on website that be today’s for remind being available is We will our call and replay.

Joining me Executive today Financial are Eric Chang, Officer. Research David Officer; Executive Dr. and President Chief Vice Chief Officer; on the Development Schmidt, Amado, call President Medical and and Rafael of and Dr. Chief Dr.

forward-looking the planned and statements may During today’s among statements. future regulatory manufacturing call, These capabilities, success ongoing things. and timing other we regarding of clinical our trials, efforts, and research filings, certain include development will and making be

and based uncertainties that These that are and the differ forward-looking actual and subject may risks to materially expectations are cause statements contained results on a of forward-looking in those change to information, involve number from current statements. assumptions

described other with Securities Form filings XXXX. Form upcoming Exchange quarter September periodic These risks the ended the XX, our quarter in XX, XX-Q well Commission, made including ended the our as and and for June are as our XXXX XX-Q for

the company obligation cautioned place these any You statements, undue disclaims to not and update on are such reliance to statements. forward-looking

over I’ll to David now Dr. turn the Chang. call

David Chang

joining our recent our us quarter call on today Good events. discuss morning third and thanks to and for our

I have at operation of year end Allogene. with what the we full complete accomplished in we pleased as company, a public very first am As our

the us leverage functions. from up, the ground all built were a by from great Allogene we give research While world-class foundation, across assembling we strong capabilities have to able Pfizer to

creating next T optimized progressed therapies. AlloCAR and successfully while X AlloCAR IND, and future advanced programs current toward T programs clinic, potential generation manufacturing, have into We pipeline

initiated the out in-house build manufacturing of capabilities. have We

the We our end, G&A have those completed functions under our also Open new headquarters. I both for roof. who to joined that September which one would at like new House thank now R&D and house in us our headquarters, To

to us many of celebration our friends new and pleased collaborators were analysts, investors, have Allogene We so in and labs. join visit

journey the about During treat position event, to now malignancies inception today, with hematological I INDs. are refractory spoke where company our we to from X patients active under in

advance of to making with facilities, believe next our that provide phase Allogene toward commercialization. is support personnel and I the growth, manufacturing development therapies building key we in as seek investment block us through the to clinical and T AlloCAR

next of growth As you the state-of-the-art phase construction facility in many of New know, of our our York, includes California. manufacturing

team. early joining team and with Allogene On seamless. our been would that Dr. Since teams we call, September, have last quarterly be of Rafael integration leadership Research other his the our arrive his in Amado announced and Development cross-functional

Rafael giving these Rafael’s refining to R&D familiarity quickly opportunity in role strategy. him us more therapy in step of this update efforts the engineered fully head of to you R&D look the I to into and later call. on the in allowed cell support forward

We with are development programs. into of the pipeline stage now lead firmly clinical

are our trial in off stated ongoing clinical myeloma program ALLO-XXX of non-Hodgkin initiation checked lymphoma. XXXX milestones, with in in we last have trial We ALLO-XXX the the our ALPHA our as patients of multiple treating and

XXXX. stated, the first plan half the we to in of have data Phase we previously from trial X As ALLO-XXX the share

need. therapies our to readily for therapies to this field clinical advancing committed moving patients viable therapy trials nascent in generate to and are of cell commercial We allogeneic

different the autologous growing than allogeneic industry autologous learned But development. as is therapy. allogeneic all our knowledge cell We firsthand therapy appreciate we fundamentally have advance and can cell insights to use of cell to therapy

outcomes To team safety cell expansion, the relationship ultimately, highly that building between robust and clinical of on focused efficacy. understanding and lymphodepletion and end, both our including, translational is a

part Turning broader our underlying strategy currently your with attention what long-term be first therapies. think to the CAR to our beyond with can other second is Notch morning, achieved our news of T generation available this collaboration technologies and Therapeutics

T by we cannot available from our programs the the patients, healthy innovation many T While revolutionize believe initial cells therapy stop from to AlloCAR collected to derived CAR have more potential field donors there. making

T the next We iPSCs. excited derived Cell Notch with Pluripotent partner are AlloCAR therapies induced from generation to develop or to of Stem

Engineered manufacturing. exclusive of the feature this gene-editing, and believe iPSC-based novel has scalability streamlined homogeneity Thymic supply, create more and cell-based to We collaboration platform, world-wide therapies of with greater Notch’s potential Niche utilizing that efficiency Notch, agreement licensing product improved

Notch with collaboration oncology T technology therapies use focused with myeloma. to cells across K Killer, engineer in multiple to initial includes Natural or develop, cell malignancies iPSC targets exclusive and and B diseases application Our and cell rights other on multiple

this aspects luminaries, the ability scientific and Notch of important to Juan Zúñiga-Pflücker work with of founders Carlos Zandstra, Dr. the Peter most is One collaboration of the Therapeutics.

pioneering cell JC for cells. techniques the other iPSC work and and their known in for immune developing differentiating are Peter iPSCs in field well into T

to Eric in research acquired and strategic details from later welcome who Given will agreement have in It review is our team we the you interest will call. and in pleasure also a my Rafael, XX% confidence on position warmly in this update the now development activities. equity technology, the this Notch. financial recent

Rafael Amado

see years recently to good to you Thank opportunities joined very I’ve in an the on call at morning role, some come. Allogene Thank various open look have today. investor but you our been in has I house months was team of the I welcome my to I work in representing and for of at and many of by Allogene events. Well, be many just behalf In to all you and of R&D. the fortunate and that people September, speaking on previous to to underway speaking you, you the excellent the meet warm pleasure opportunity forward an with of of had am David, more and to happy you, today

to as planned. continues ALPHA accrue ALLO-XXX dose escalation Our study

amendment to also been be redosing ALPHA the disease have include further dosing who explore ALLO treated with patients criteria ALLO-XXX. will therapy have to filing the We patients for optimal and protocol CDXX to trial the whose of and expand schedule current of previously an enrollment autologous directed progressed.

clinical key parameters translational up depth [assays] earlier. studying are lot corollary David the variety a We Indeed, as [ph] dose of relationship mentioned we externally outcomes both internally a between have about the lymphodepletion, us clinical in allogeneic are to optimal that and setting of of cell done being made progress of in informing with will process and that work the and conditions close is and the best properties the outcomes properties. development setting. lead optimal associated This with optimal the elucidate supply fully clinical to in collaboration allograft that pharmacodynamic research will team the the

actively clinical our trial and we’re accruing QX, during and initiated ALLO-XXX patients. We UNIVERSAL treating

anti-BCMA myeloma We ALLO-XXX, patients. CAR are for developing therapy T of our relapsed/refractory allogeneic multiple the treatment

trial, submission. of be get X continue I’d a design. goal about of remind ALLO-XXX the potential which optimal with levels for tolerability of a dose you briefly X assess could to a an designed BLA increasing Phase safety UNIVERSAL many We study, of like ALLO-XXX and identifying so to study of the to Phase study questions ALLO-XXX pivotal its is The dose for

for part our had portion myeloma, anti-CDXX and proprietary removed. studies, a be plan the also utilize dose therapies In in least failed to the AlloCAR prior monoclonal the fludarabine patients component UNIVERSAL X XX who a of chemotherapy milder exploration lymphodepletion The regimens CDXX ALLO-XXX, will trial assess design. trial the escalation potential up to study, with of allow lines the to stepwise T will this designed of relapsed/refractory a specifically at lymphodepletion plus as cohorts we X do enroll cyclophosphamide of additional X antibody As where regimen. main to study multiple

cell be assessing activity look end and first the sharing by of ALLO-XXX such anti-tumor As of endpoint regimen. determinants of data expansion trial lymphodepletion tolerability, XXXX. from we a various will look anticipate the ahead, with for as key success a this as We safety, we

in Servier, and our that UCARTXX pediatric clinical adult and partners about our the moving to expect of development excited X strategic We’re on research in We very to trials also Phase programs. XXXX. continue direction pleased and into progress ALL announced that remain

fortunate Scientific of Advisory have first what very I the to scientific cell of is and pioneering access productive attended. ever Allogene what’s that meeting industry, space one I have best SABs uniquely one at my believe the Board showcase therapy to advisory the most the We’re and boards allogeneic in in science

new and the sort meeting of the trial our team expansive our focus tumors. research our technology and to innovations products that the address design feedback and innovative solid This malignancies in of pipeline are including hematologic on

research investigate the nucleic highlighted T already to novel will acid Under lymphocytes, Levy more system Robert or Ronald with are allow Allogene a including work Dr. delivery deliver this researchers, University of collaboration safely in genetic Stanford flexibly into partnership the including some September. efficient effectively, ex and cells signed collaboration, DNA RNA vivo. Dr. engineering and Waymouth, to have with pursuing, Paul Wender, in we Dr. We

by innovation and see next SABs guidance pursuing. would our more efforts projects The our the on am year. from I also we validation our the very we from forward invaluable internal look excited research that unveiling to are over teams

like Eric. call over now will turn to to I the

Eric Schmidt

of Thank a brief you, Allogene’s Rafael. overview I will provide financials.

XXXX. today can be in totaling as found third financially our Additional cash, XX-Q, September and be release $XXX.X with million which quarter of detail earlier our with filed XX, We and our the results in on equivalents will issued cash financial strong remain SEC. investments press

million, is milestone In QX the R&D a study compensation ALLO-XXX. the $X which on $XX.X million includes third to of associated partner our payment which expense of quarter, expenses $X.X our stock-based million development with were Cellectis, also initiation includes and research non-cash Universal in the expense.

non-cash expense. administrative quarter for and $XX.X the compensation expenses which million third $X.X million of stock-based General includes were a XXXX,

$XX.X Our third $XX.X per share net compensation including million. million, XXXX loss $X.XX for stock-based non-cash of was or quarter expense of the

the As we’ve been as quarters, full of time and with invest capabilities agreements. XXX manufacturing in cross highly business noted out well heavily in programs clinical as continue strategic We’ve advancing focused development build also the now functions on our previous to employees. our executing hiring we

noted million, Notch at therapies. to develop over As a and call, next research of an ability Notch. provide are with equity in and exclusive earlier million the funding payment about XX% $XX equity the will of we iPSC-based $X very the in for agreement, terms collaboration preferred a our excited term collaboration Under investment return Allogene the generation this of upfront position allogeneic

of achievement come committee. Pre-clinical retain and any and eligible as candidates research Notch research, that the payments rights potential all commercialization will be development certain the Allogene will of of to by direction the to may worldwide lead will milestones joint would as future tiered candidates. of collaboration upon under royalties. be receive well out clinical development conducted commercial development and Notch

associated Including guidance. position million. the estimated to million net $XXX remain expenses compensation with Full-year transaction, $XX non-cash be includes to losses to reiterate $XX of expected we net loss the between in an expense based $XXX are This million. million stock and XXXX Notch our

of the your With that will brief review our we call for open questions. financials, now

Operator

Instructions] [Operator with you. from first Jefferies. Amin Our Thank question comes Biren

now is open. line Your

Biren Amin

Thanks half Maybe guys. start next progress. the based questions taking first I how would many just bit little data hi, for Yeah, my and can the could if that potential time in would you on analysis, be XXXX, all And, on patients with steps? what have talk guess, you at David? a ALLO-XXX, I about of of congrats

David Chang

answer those happy we’ll your Dr. I’m to to questions Biren, to Amado. And direct questions. Rafael going be

Rafael Amado

hi, Biren. Yeah,

And trial able quite be year. to first progressing first planned. continue presentation that to that which evaluate be will half We decided this guiding well of is approach. to enough we contains our the as is the one time, same So allogeneic information the would the

statements So enough and will patients safety make be that to expectation able is corollary we parameters. our efficacy, to have about

Operator

you. Thank

next with from Cowen Nadeau and Phil comes Our Company.

is line now open. Your

Philip Nadeau

ALLO-XXX Good morning. on Thanks is ALPHA for question My taking Trial. question. also my the

ALPHA that you the cell of in During you’re Trial, were the lymphodepletion depth the you couple fact change a to how to affects schedule prepared remarks, working dosing figure of you And mentioned out of times that expansion. you XXX. mentioned going from

the we contemplating Thanks. XXX initial started to can into what change are that accomplish? changes specifically to And, are So you investigate because dosing those of I schedule these you read guess, trying what and seen in for comments patients? what you’ve you’ve

David Chang

morning. Good Phil. Yeah,

Let David is Chang. me take that This question.

of this the that mean, some some X are assumptions the as test design to things the that is So I the questions always we confirm we the Phase Phase study at, into went of view X about to study. Phase a really X. well of looking And as unknowns

of And and different us X to are quickly the key, that in X we the with And move the as progress goal talked is Phase X, as the will about, questions flexibility that many on end, we up schedule ask. X at there as want of Phase the doses have into so the coming because to right and enable Phase possible. Phase

Phase So is in ALLO-XXX as starts flexibility. clinical a simple lot sometimes X, and it it our with times, with go to first goes. case a opportunity as of of beginning to the given studies very study we that the study, In from of protocol the lot amend a elected a the take company, ALPHA

it a all what that talking part about So none is plan are we reflection original had. are things of is these, the we seeing. the of of But we that

Operator

you. Thank

with Cory JPMorgan. from comes question next Our Kasimov

now Your line open. is

Unidentified Analyst

Hi, Cory. this on for is Galvin

the decision data; kind do on see, or it any thoughts any you now? just the and deal, thoughts Did deal why was to your did timing, you Notch drove get to there? what wanted Thanks. on the pre-clinical the decide of clinical Just

David Chang

is this David Yeah, Chang.

Let from are me the are times. the thinking And advance future the started times allogeneic And we This that now, using numerous that oncologists. mean, about general trying where lie, the we think take allogeneic we the how to also T T in that. is as have talked donor. therapy advance have healthy several CAR talked into I about the therapy. field we the CAR about may I we

cell as using as really potential And making we manufacturing the believe well the to the gene-engineering renewable has the scalable. eventually fine-tune more iPSC-derived that source

that may you somewhat say, this always opportunistic. now? have we to why I something So is be think

mean, reasons I this the I this these the then into so of Notch, iPSC T some I deal scientific differentiation believe two to is JC Zúñiga And the define that Dr. us of drove really Peter is, and founders. scientific that Dr. mean, cells. also founders they of Zandstra.

Notch’s so really And or T deal. really differentiation platform And the that this to platform the Niche – of us allows far, to [ENT] [cell-free as [ph] are get serum-free platform synthetic a in Engineered us functioning cell. [ph] drove provides they iPSC what the bringing, based] a the Thymic that’s Engineered that

scalable have what and GMP what more believe process. and Scientific they founders, a potentially amenable we to be manufacturing

Operator

you. Thank

Our next Piper comes with Tyler question Buren from Jaffray. Van

Your line is now open.

Tyler Van Buren

progress Hey, on during quarter. good morning, the the Congratulations guys. all

include you’re an any regarding guy’s I your was pre-clinically discussed CDXX. had previously clinically just in what prepared patients treated the to if with are that talk who amendment resulted Just curious observations was with another that question, about. that remarks change, decision willing to in are there or

Rafael Amado

Yeah, hi, Rafael. this is

progressing So the potentially as we’re approach allogeneic been the about other test ways settings. to thinking study, in we’ve

that know, for other you options, no are although are Lymphoma, there Non-Hodgkin benefit. don’t outcomes as two-thirds excellent have So that the of patients in still patients

have months. that progress respond poor actually of don’t are quickly first And the patients graph. there those patients And really or X within many

right don’t Although phenotype. T any exhausted the or are release they requirement, either the cells have

still the in trying before provided single different that, saw [CARTA the sense. that [ph] we had make CDXX. base V, chain that a would approach so, And an patients what allogeneic And is] tumor these was

patients, It to first that would whether as of of a allogeneic patients I be, therapy, therapy is, the to that also importantly, of have can work of be field. something benefit failed all, think proof which but autologous very in would source more concept

population behind rationale T, options. the the once few that autologous it, sizeable fail knowing this So rationale, they that that was and a have is CAR patient very particularly they

Operator

Thank you.

comes Our Murphy BTIG. with next from Amanda question

Your line is open. now

Amanda Murphy

extent well, a question so that have the to get just morning. about the to or sense XXX of talk complete And you’ve if a don’t how able you in and are to T last? this sense, they’ll good thinking long go can see you setting? if to physicians how as I transplant responses, transplant Do try the any to been the get curious, you centers do know on CAR Hi, T the or durability CAR the had

David Chang

Amanda, is David. this

your take question. me morning. Let Good

Amanda Murphy

Hi.

David Chang

as mean, the So we very investigators. I closely act have do with study, the to we

we we advice And have getting that some factors amendment of investigators’ from and that the into that also are interest about, talked them.

received Rafael and reflects as patients it talked received T field not unmet CDXX inclusion about, as just who interest identifying the growing an And previously of CDXX, previously as the the have previously treated as responded the autologous CAR who the in patients have one being of treatment need.

we that So definitely in going investigator interested sort are the with of pursuing avenue. and

rate are last really progressing in with we investigator we questions I’d really make what stated plan, and the of of we the the the XXXX. studies. I according With say And maintaining they’re other respect is I first how mean, seeing have to things, I we’re in happy X enrollment, time. clinical meaningful study. in I you in due in know and mean, of a one, much like as that about to with this which that are And mean, have the to the I many is provide of the think project cannot the the going position to been we that be I would clinical very this half preceding update the support statement we the prepared over quarters, asking be

Operator

Thank you.

Oppenheimer. question next Mark from Breidenbach Our comes with

Your now is open. line

Mark Breidenbach

guys. morning, good Hey,

a me I question ask if can. X Let part

that First you tested you being think to regimen? diverge lymphodepletion think of all, to X will being that regimens do amended exploratory of the each protocols the are that do the terms UNIVERSAL? from what’s other similar be very protocol going in ALPHA into lymphodepletion Or in are

so, cells also of And differentiation just question part is competitors? on methodology treading It technology cells IP you that how Notch quickly from Thank I avoids on a second like Notch’s some T iPSC collaboration. comment Notch focuses the for sounds out But maybe NK existing I’m the if as core have proprietary iPSCs of well. in on the focusing program the of if induction. can and And really the on there has that’s wondering, you.

David Chang

So let those me Mark, take – let questions. both of me

are expiration study T, one the lymphodepletion respect of something built a we do with different we the have about us gives mean, that has you’ve to allogeneic work. The of AlloCAR the to control reduction that doing T what out agent, in a proper XXX essentially overcome think CAR first are which have pointed many any the question our how lymphodepleting will allogeneic, selective lymphodepletion, to areas as for ALLO-XXX, lymphodepletion, of really outlined about that is And to some is in the therapy key of be of which using ways the some UNIVERSAL biological the that study. the ALLO-XXX as I our to we this

programs it. use different are with the will modifications And selective in test sort of we this right doing to go how it, are exactly, and ALLO-XXX, the But that don’t key into can of we this do study, how – biologic the is bearing conceptually, testing things it, really so XXX reveal lymphodepleting is both around think, the I we we agent. are it’s place that

The second what’s the about question around unique Notch. really

attraction as scientific of synthetic ETN with behind method their platform differentiating commercializing partners, manufacturing iPSCs clinical that, the believe guys – way. who said, T any and in hopefully always I’ve the cells T some into said and And as at we provides eyeing there in you where in differentiate iPSCs wise create founders serum-free, think partnership We cell from differentiation the quality scalable the studies cells. therapies. that collaboration day, think, a cell-free into people and this as a sufficient Along T think, to and Notch goals I And able I we’re aspects many cells. a iPSC in Therapeutics said. are field towards iPSC-derived being the towards to is really looking I’ve really this the the Notch platform, of quantity different about I’ve real

Eric Schmidt

Eric. is this Mark, And,

have we to going on as performed much not who’s this the IP legal here patent diligence we strong can side, the you bench. are matters, appreciate, but be On due team discussing

Operator

comes question next Our William Prasad with Raju Instructions] from Blair. [Operator you. Thank

Your line is now open.

Raju Prasad

then, making on about in assays congrats of be the to just it along when and of before maybe lines question, guess, putting more maybe you’re just the of thinking a reactivity you’re provide I’m you’re on thinking kind the color follow-up a that? just I you based thinking or sense of how engrafting Can the you what Flu/Cy regimens which changing will guide touched trying you’re would regimens the about changing higher you it based? taking progress. for more if reducing XXX, decisions? about and do the a of how hierarchy Thanks. bit when the on Thanks a Is And get little preconditioning. –

David Chang

are Seems protocol Raj, for that the question. lot thanks Okay, the questions making. like of a about we amendment

that the amendment, said, discussing this be hypothesis. different to been And in to have I’ve indicated we previous adjustment making we that will from the have fact, in protocol is sometime. we As test protocol internally communications something some

And potential really driven that lymphodepletion benefit clinical is that’s focus on necessarily questions, have from is about clinical adjusting stay the study. going of we I maximizing we’re would of and one this centered-around So out But your ALLO-XXX. the the coming of that seen. our main data silent really to ALLO-XXX of say that relatively the not based to data

strategy. is differentiated differentiating know, proprietary you this there. from lymphodepletion, what’s a the As fact provide And believe that this we out factor unique that can selective in we It and potentially our our lymphodepletion is significant agent. is

maximize plan we underlies different study. of to obviously, in to want So aspect ALLO-XXX, things test actions we ongoing and the then the that and about that ALPHA

Operator

you. Thank

from comes Newman next with Our John Canaccord. question

open. now is line Your

John Newman

Hey, good my guys. morning, for Thanks taking question.

you. would current you to changes lymphodepletion as and in or instituting ask – maintain But to protocol some curious, things be will as we having going patients regarding curious doing additional well changes potential to are Just the you order if the some the forward the out? how turn Thank to investigate see about study those question just amendment. be if sorry another

Rafael Amado

the I I’m not understood entirely enrolling are changes going that we perhaps, XXX, cohort. to earlier of mean, I whether go in in the is this X this all this to details if, continue study. reiterate mean, with I And essentially, you what just I sure But asking said, Rafael. think, to is don’t we’re do or I Phase are making to changes going point investigative this going to how into David this. want So

[ganpast least The first and you ALLO-XXX that is you designed of both studies that trada] maximum a study study thing design So lowest anonymous you it in that to actually different optimize was X – to know and product, going that the was dosing. X and for the to both of – possible Phase for for which it’s to benefit only And toxicity. choice fitting before may dose are the was Phase – launch the amount the doses dosing of of want the lymphodepletion

amendment the So in plan. time about make not needed out, this to some doses we to was out. we that, planned early something going on order in found rolls back the And as And we that it to don’t and be anticipate has do and accrued very evolving obviously, the patients to it was it’s treated. study when will

me that’s it just doesn’t clarify. to your please So answers if and I question, think hopefully ask

Operator

Thank you.

next Securities. with Our comes Michael from question Schmidt Guggenheim

is open. now Your line

Kelsey Goodwin

it’s been taking kind for market. due given There and between stage this does and frontrunners now anti-BCMA X guess, for differ Hey, Michael. T a is is question. as bar bar anti-BCMA set on and suspended auto you competitive think for clinical disadvantages? advantages the our by what bar obviously this the of is maybe the you. you’ve high Thanks do Kelsey approaches XXX versus of I kind Thank to AlloCAR seen

David Chang

we and know we we from be AlloCAR This how for I and on mean, question. proceed experiments scientific what working based in answer is T clinics. the David, the preclinical thanks the I’ll Kelsey, that. feel should the

allogeneic CAR basis. should same baseline treated Our about I T. and safety autologous a efficacy on – of – that in level based approach a provide so on mean, the at is number that is assumption

could expectation. into our I study. that’s see So that from we mean, assumption. will that baseline in better things baseline certain obviously, there leave a we the perspective backward to I really efficacy are to that have haven’t mean, clinical our

one however, of add therapy. of autologous that limitations I T the CAR cannot receive therapy the to is patients would, wait who current

the T If restoration of studies XX% enrolled and CAR space T in the cell you XX% studies space they to go and in review that who being the approval back of the Yescarta. the manufactured. the that cannot still receive the Kymriah of – left the CAR simply cells, unable because in patients CDXX clinical autologous to wait to

think several potential obviously, can simply with really led in And that the I on CAR treat, I say think, – basically are if would into allogeneic T lead intense improvement provide. if made to we more based data efficacy to logistical available depletion model the allogeneic, treat our T made go CAR the cells patients are being treated. as And the cells be is from once the patients be aspect there to could we and the look to that the the patients the at have the to potentially

Operator

Thank you.

with from comes question Stifel. Burnett next Our Ben

if Ben, is line your un-mute. is line open. please now muted, Your

Benjamin Burnett

and Good also Apologies. you. the congrats a I had the competitive progress. Thank on landscape. morning on question

so wanted messaged a CAR to Thanks window program about CDXX ALLO-XXX CDXX you is talked the there data they candidate? I from BioSciences, Precision So to you’ve guess, I the data? could T that and BioSciences differentiates can releasing more that ALLO-XXX that Precision of have details ask, from some potentially much. And they have technological within talk

David Chang

Yeah.

since obviously and I having allogeneic. lesser And year-and-a-half, said. and have I the to cell in interest for year are field aware the in mean, last the the the pharmacologist over we seen therapy think Precision what the have BioSciences, and good field we a allogeneic field, is created really they’re of this And And what the is is of we doing advancing So they tremendous growth clinicians. Allogene. this I think

the there creation remain from is end, from As is approaches this companies taking. that we at allogeneic of as think how are approach. confident making know, other and approach we cell allogeneic different you we are the some feels in I out are We differences each learn this accelerate going taking. – And several that different the are to there in very

have review that Disease we as UCARTXX ALL is viable. things expansion I that approach treated are said, when patients based approaches the on setting. And And which our genetic make controls the Graft-vs-Host cell provide and the the sure the efficacy and the that the engineering are number the the early key of allows these in mean, in UCARTXX, essential also studies, I data has the

I that think ALLO-XXX strengths and is taking as the we we And program. are that ALLO-XXX one of advance forward

Operator

Thank you.

ROTH comes with Our Tony question next Capital Partners. from Butler

line now open. Your is

Charles Butler

very Thanks much.

First actually of applaud the all, I amendment.

first question goes may would really that XXX you to new as vary combination, will? learnings – through and what experiment patient the entirely population UNIVERSAL you and with with be with each be it the Flu/Cy. – different capture think able you Do assume between becomes So an it it the ALPHA, reasonable you if differences to

educated human follow-up that is fact are in are kill that but order do you applause that may not I T you in very appropriate be can cells actually, but just iPSC much. sufficiently if Thanks deal, derived actually tumors. a behave T on imposters, cells, like normal Notch, to convinced And for to T cell

David Chang

Okay.

question, that to Rafael for to question thanks the Tony, first defer I’m So, and going take second to I’m going for question. especially, the

the increased is Can the T you’re to one of one CAR efficacy, the with believe advantages what I of the the an think upon therapies, important T you is unique depth target recognition of ones the especially iPSC, most expand, the that using get me to and that asking T cells in. response of generate question functioning number, is And the where cells’ T, cell-based the cells? the that’s questions. on the we So that the the ability real that’s I with of

And as cells. we can we I they indications have they that do shown exclusive That’s the have that T propriety well, that. to platform, which Notch you the can said, ETN is are think, everybody using after, that generate true. And license going platform, for not that may that functioning

iPSC, whether you fully that functioning not is can I mean, answered of T the generate the cells. is this areas really in one

and data, amenable functioning the we founders moment, really, be when jump when this that that like large-scale they that besides discussions the that also, can into record, differentiate was proprietary to collaboration. So they they with had manufacturing. doing data research And the and that were really show that iPSCs their a to of is Therapeutics, And Notch the might drove track mean, what us having aha due I reagent. the And shows fact really it this diligence cells. for T

Operator

Thank you.

Rafael Amado

different that, differences first Tony. and the a it’s between ALPHA that UNIVERSAL hi, ALPHA I say B, earlier, and study, what so, you data to would UNIVERSAL so the have the question Yeah, we have and Right, is as is and similarities This we disease. study. about naturally; is your A, the know, for

benefit/risk, and And with so, to obviously, maximize you try alloreactivity the lymphodepletion optimal to minimal trying to the of already the have toxicity. to anti-CDXX idea potential designed get with reduce

that different move is be to we point as of the I that look and the David the regimen X as Phase different and you before, for at lymphodepletion the alone, it diseases. further making, the of lymphodepleting studies studies in the mentioned time to may because And it’s with with now possible same think doses, I objective. again ALPHA The condition different, were

And Phase we these want the benefit/risk. is so that’s during phase X really along the do, Phase have carefully start of maximum greatest of sort what potential the two when we march to the we to that trials, X to study, derive very

UNIVERSAL. we more and tell speculative. ALPHA study, feels and see as modifications will So see that what may time you in future. we’ll update to the we we in And the make patients But also happens

David Chang

mean, X that that this recognizing many amendment, here. having X to in really with this in warranted the that course anywhere mean, amendment is is the am having between through of number the amendments field for again. X. David by surprised involved Phase studies, X Tony, have protocol different something Thanks way, I protocol is I in been the on been Yeah, will questions been the that involved somewhat of I XX and Phase every studies have Phase so I

part a a So doing X amendment. more par of as as questions I I to we’re and as that in has But about a see lot Phase routine have the you know of of it do one that why protocol the all study.

Operator

I any turn the back Thank like That over concludes management today’s call to session. for would to additional now you. question-and-answer comments.

David Chang

on you we us you may as XXXX. of you support out close ASH ongoing for your to now forward our other thank we as you and the joining seeing at for conferences Operator, thank progress And today. We Well, call disconnect. of Allogene clinical programs. many look

Operator

and program. Ladies participation conclude conference. does gentlemen, This you thank in for you. the today’s Thank

You may and disconnect. off now log

Allogene Therapeutics (ALLO) 5 Nov 192019 Q3 Earnings call transcript